Literature DB >> 14529468

Medicinal and genetic approaches to the treatment of mitochondrial disease.

Eric A Schon1, Salvatore DiMauro.   

Abstract

Although great progress has been made in our understanding of the molecular bases of mitochondrial disorders due to defects in the respiratory chain, little exists in the way of rational therapy. Possible therapeutic approaches include: palliative therapy; removal of noxious metabolites; administration of artificial electron acceptors, metabolites, and free radical scavengers; genetic counseling; and gene therapy. There has been progress with each of these approaches, although much work remains to be done. Finally, a novel approach to treating a specific mitochondrial disorder, MELAS, is presented.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14529468     DOI: 10.2174/0929867033456503

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  8 in total

1.  Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo.

Authors:  Swati Biswas; Namita S Dodwadkar; Pranali P Deshpande; Vladimir P Torchilin
Journal:  J Control Release       Date:  2012-01-20       Impact factor: 9.776

Review 2.  Insight into nanoparticle cellular uptake and intracellular targeting.

Authors:  Basit Yameen; Won Il Choi; Cristian Vilos; Archana Swami; Jinjun Shi; Omid C Farokhzad
Journal:  J Control Release       Date:  2014-06-28       Impact factor: 9.776

3.  Surface modification of liposomes with rhodamine-123-conjugated polymer results in enhanced mitochondrial targeting.

Authors:  Swati Biswas; Namita S Dodwadkar; Rupa R Sawant; Alexander Koshkaryev; Vladimir P Torchilin
Journal:  J Drug Target       Date:  2011-02-25       Impact factor: 5.121

4.  Surface conjugation of triphenylphosphonium to target poly(amidoamine) dendrimers to mitochondria.

Authors:  Swati Biswas; Namita S Dodwadkar; Aleksandr Piroyan; Vladimir P Torchilin
Journal:  Biomaterials       Date:  2012-04-01       Impact factor: 12.479

Review 5.  Potential therapeutic benefits of strategies directed to mitochondria.

Authors:  Amadou K S Camara; Edward J Lesnefsky; David F Stowe
Journal:  Antioxid Redox Signal       Date:  2010-08-01       Impact factor: 8.401

6.  Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate.

Authors:  Shanta Dhar; Stephen J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-10       Impact factor: 11.205

7.  Structural insights into oligomerization and mitochondrial remodelling of dynamin 1-like protein.

Authors:  Chris Fröhlich; Stefan Grabiger; David Schwefel; Katja Faelber; Eva Rosenbaum; Jason Mears; Oliver Rocks; Oliver Daumke
Journal:  EMBO J       Date:  2013-04-12       Impact factor: 11.598

Review 8.  Three-parent babies: Mitochondrial replacement therapies.

Authors:  Hana Carolina Moreira Farnezi; Ana Carolina Xavier Goulart; Adriana Dos Santos; Mariana Gontijo Ramos; Maria Lectícia Firpe Penna
Journal:  JBRA Assist Reprod       Date:  2020-05-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.